Warren Stern

Founder at HO2.1 Annex Fund LP

Warren Stern

Warren Stern

Founder at HO2.1 Annex Fund LP

Overview
Career Highlights

HO2.1 Annex Fund LP
Research Triangle Pharmaceuticals LLC

RelSci Relationships

582

Birthday

1945

Age

73

Relationships

Senior Vice President-Biometrics & Regulatory at vTv Therapeutics, Inc.

Director of Clinical Pharmacology at Thomas Jefferson University Hospital

Consulting Pediatrician at Duke University Hospital

Co-Founder & General Partner at HO2 Partners

Co-Founder at HO2 Partners

Co-Founder at Origin Ventures

Senior Program Officer at The Burroughs Wellcome Fund

Senior Programs Assistant & Data Specialist at The Burroughs Wellcome Fund

Senior Program Associate & Database Specialist at The Burroughs Wellcome Fund

Program Officer at The Burroughs Wellcome Fund

Subscribe to RelSci Professional to see 582 more Relationships
Paths to Warren Stern
Potential Connections via
Relationship Science
You
Warren Stern
Founder at HO2.1 Annex Fund LP
Education
Class of 1969

Indiana University is a major multi-campus public research institution, grounded in the liberal arts and sciences, and a world leader in professional, medical, and technological education. Indiana University’s mission is to provide broad access to undergraduate, graduate, and continuing education for students throughout Indiana, the United States, and the world, as well as outstanding academic and cultural programs and student services. Indiana University seeks to create dynamic partnerships with the state and local communities in economic, social, and cultural development and to offer leadership in creative solutions for 21st century problems. Indiana University strives to achieve full diversity, and to maintain friendly, collegial, and humane environments, with a strong commitment to academic freedom.

Career History
Founder
Current
Senior Vice President-Drug Development
2003 - Prior

DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.

Subscribe now for extended career history
Transactions
Details Hidden

QRxPharma Ltd. raised money in a private placement transaction